Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

QUALITOP

Financiado

Cerrado

Monitoring multidimensional aspects of QUAlity of Life after cancer ImmunoTherap...

Monitoring multidimensional aspects of QUAlity of Life after cancer ImmunoTherapy an Open smart digital Platform for personalized prevention and patient management "Cancer immunotherapy brought about significant progress in cancer treatment. It resulted in high efficacy in some cancers; e.g., up to 60% objective response rate in melanoma and 80% complete response rate in acute lymphoblastic... ver más

30/06/2024

Laboratoire d’Ecol...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

CNRS UMR 5023 No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-06-30

SC1-DTH-01-2019: Big data and Artificial Intelligenc...

I+D

Cerrada hace 5 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

Laboratoire d’Ecologie des H...

889.38K€ | Lider

HOSPITAL CLINIC DE BARCELONA

N.D. | Participante

ATMO BFC

N.D. | Participante

UNICAL

278.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ASCAPE Artificial intelligence Supporting CAncer Patients across Eu... 5M€ Cerrado

CAPABLE CAncer PAtients Better Life Experience 6M€ Cerrado

PERSIST Patients centered SurvivorShIp care plan after Cancer treatm... 5M€ Cerrado

TED2021-132025B-C42 ESTRATEGIAS PREVENTIVAS INTEGRADORAS PARA EL CANCER Y LAS EN... 569K€ Cerrado

4D PICTURE Design-based Data-Driven Decision-support Tools: Producing I... 9M€ Cerrado

CECM Centre for New Methods in Computational Diagnostics and Pers... 400K€ Cerrado

Duración del proyecto: 56 meses Fecha Inicio: 2019-10-28
Fecha Fin: 2024-06-30

Líder del proyecto

CNRS UMR 5023 No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Cancer immunotherapy brought about significant progress in cancer treatment. It resulted in high efficacy in some cancers; e.g., up to 60% objective response rate in melanoma and 80% complete response rate in acute lymphoblastic leukaemia. Nevertheless, two main challenges still impede improving cancer patients’ health status and quality of life (QoL) after immunotherapy initiation: 1) a crucial need for predictive markers of occurrence of immunotherapy-related adverse events (IR-AEs) to predict and improve patients’ health status and promote their QoL; and, 2) the lack of knowledge on patients after start of immunotherapy outside randomised controlled trials. To reach these goals, significantly more diversified sources of data are required. Project QUALITOP aims at developing a European immunotherapy-specific open Smart Digital Platform and using big data analysis, artificial intelligence, and simulation modelling approaches. This will enable collecting and aggregating efficiently real-world data to monitor health status and QoL of cancer patients given immunotherapy. Through causal inference analyses, QUALITOP will identify the determinants of health status regarding IR-AEs and define patient profiles in a real-world context. For this, heterogeneous data sources (big data), both retrospective and prospective --collected for QUALITOP from clinical centres in four EU countries—will integrate lifestyle, genetic, and psychosocial determinants of QoL. Using machine learning approaches, QUALITOP will provide ""real-time"" recommendations stemming from patient profiles and feedbacks via the Smart Digital Platform. Furthermore, an increased visibility on patients’ behaviour, a better IR-AEs prediction, and an improvement of care coordination will help analysing through simulation modelling approaches the gain in cost-effectiveness. Guidelines will be issued over the short and long-term. "

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores